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Abstract
An optimal treatment for patients with diffuse obstructive arterial disease unsuitable for catheter-based or surgical
intervention is still pending. This study tested the hypothesis that extracorporeal shock wave (ECSW) therapy may be a
therapeutic alternative under such clinical situation. Myocardial ischemia was induced in male mini-pigs through applying
an ameroid constrictor over mid-left anterior descending artery (LAD). Twelve mini-pigs were equally randomized into
group 1 (Constrictor over LAD only) and group 2 (Constrictor over LAD plus ECSW [800 impulses at 0.09 mJ/mm
2] once 3
months after the procedure). Results showed that the parameters measured by echocardiography did not differ between
two groups on days 0 and 90. However, echocardiography and left ventricular (LV) angiography showed higher LV ejection
fraction and lower LV end-systolic dimension and volume in group 2 on day 180 (p,0.035). Besides, mRNA and protein
expressions of CXCR4 and SDF-1a were increased in group 2 (p,0.04). Immunofluorescence staining also showed higher
number of vWF-, CD31-, SDF-1a-, and CXCR4-positive cells in group 2 (all p,0.04). Moreover, immunohistochemical staining
showed notably higher vessel density but lower mean fibrosis area, number of CD40-positive cells and apoptotic nuclei in
group 2 (all p,0.045). Mitochondrial protein expression of oxidative stress was lower, whereas cytochrome-C was higher in
group 2 (all p,0.03). Furthermore, mRNA expressions of MMP-9, Bax and caspase-3 were lower, whereas Bcl-2, eNOS, VEGF
and PGC-1a were higher in group 2 (all p,0.01). In conclusion, ECSW therapy effectively reversed ischemia-elicited LV
dysfunction and remodeling through enhancing angiogenesis and attenuating inflammation and oxidative stress.
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Introduction
Coronary artery disease (CAD), which develops initially from
endothelial dysfunction followed by plaque formation and
propagation before the development of obstructive syndrome,
remains one of the most notorious killers in industrial counties
[1,2,3]. Despite the advance in pharmacological therapy [4,5],
mature technique of coronary artery bypass grafting (CABG) [6,7],
newly developed instrument-supported percutaneous coronary
intervention (PCI) [8,9] for restoring myocardial perfusion, and
current guideline focused on management strategy [10], restenosis
due to preexisting systemic endothelial dysfunction and diffused
vascular obstruction remain the Achilles’ heel that limits
therapeutic success and long-term prognostic outcome
[11,12,13]. Of importance is that quite a lot of patients suffering
from diffuse obstructive CAD, for whom pharmacological
treatment is of limited help, are not suitable candidates for
interventional therapy through either PCI or CABG. The majority
of these patients, therefore, are still in a helpless clinical situation.
Hence, finding a safe and effective therapeutic regimen for
patients who have diffuse obstructive CAD, especially those
unsuitable for coronary intervention, is of utmost importance for
cardiologists and cardiovascular surgeons.
Shock wave (SW) therapy can deliver a sequence of transient
pressure disturbances characterized by high peak pressure
(100 MPa), fast pressure rise (,10 ns), rapid propagation, and
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directed to a specific target area with an energy density in the
range of 0.003–0.890 mJ/mm
2 [14] [15,16,17]. A number of
studies have revealed that not only does SW provide mechanical
means of treatment such as in lithotripsy for kidney and ureteral
stones, but its low-energy form (0.03 to 0.11 mJ/mm
2) also
produces a series of subtle biological changes in the musculoskel-
etal [18,19] and cardiovascular system [15,16,17]. Additionally, in
vitro studies have demonstrated that extracorporeal (EC) SW
therapy can enhance vascular endothelial growth factor (VEGF)
mRNA expression in cultured human umbilical vein endothelial
cells [15] and in rat bone marrow cells (BMCs) [20] as well as
promote BMCs differentiation into cells with endothelial pheno-
type [20]. Hence, by applying appropriate energy to ischemic
organs [15] or tissues [18,21], ECSW therapy can attenuate
inflammatory response and induce angiogenesis/vasculognesis
[15,18,21]. Thus, ESCW therapy may provide promising
therapeutic benefits in relieving the ischemic syndrome for patients
with diffuse obstructive CAD who are not suitable candidates for
interventional therapies. However, prior to utilization of ECSW
for daily clinical practice, a pre-clinical experimental model for
verifying its safety and efficacy is mandatory. This study utilized a
mini-pig ischemic heart model to test the hypothesis that ECSW
therapy may improve ischemia-related left ventricular (LV)
dysfunction and attenuate LV remodeling.
Methods
Ethics
All experimental animal procedures were approved by the
Institute of Animal Care and Use Committee at Chang Gung
Memorial Hospital – Kaohsiung Medical Center (Affidavit of
Approval of Animal Use Protocol No. 2006121501) and per-
formed in accordance with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 85–23, National
Academy Press, Washington, DC, USA, revised 1996).
Animals, Protocol, Procedures
Male mini-pig (Taitung Animal Propagation Station, Livestock
Research Institute, Taiwan), weighting 16–18 kg, was anesthetized
by intramuscular injections of ketamine (15 mg/kg) and main-
tained with an inhalation of 1.5% isoflurane during the
procedures. After being shaved on the chest, the mini-pig was
placed in supine position on a warming pad at 37uC followed by
endotracheal intubation with positive-pressure ventilation
(180 ml/min) with room air using a ventilator (Sn: Q422ZO,
SIMS PneuPAC, Ltd.). Electrocardiographic (ECG) monitor and
defibrillator were then connected to the chest wall.
Under sterile conditions, the heart was exposed through mid-
thoracotomy. After gentle removal of the pericardium, an ameroid
constrictor (Research Instruments NW, Inc. Lebanon, OR, USA)
was applied to the mid-left anterior descending artery (LAD) just
distal to the first diagonal branch. The constrictor constitutes an
outer layer of stainless steel and an inner layer of fluid-absorbing
casein that swells as it slowly absorbs body fluid to produce an
inward concentric expansion. It usually required several weeks to
create a significant stenosis over the mid-portion of LAD.
Neither regional ischemia nor wall motion abnormality was
noted over LV anterior wall after the procedure. The absence of
cardiac ischemia was further confirmed by complete ECG following
the procedure. Ameroid constrictors were applied to mid-LAD in
twelve mini-pigs which were equally divided into group 1
(Constrictor over LAD only) and group 2 [Constrictor over LAD
plus ECSW (800 impulses at 0.09 mJ/mm
2) after the procedure].
The muscle and skin were then closed in layers. The animals were
allowed to remain on the warming pad and recover under care. A
flowchart of the experimental procedure is shown in Figure 1.
To compare the findings at cellular-molecular level between
normal and disease animals (i.e. groups 1 and 2), standard control
samples were obtained from six healthy mini-pigs with similar age
and body weight that served as normal controls.
Application of ECSW to LV Myocardium of Mini-Pig
By day 90 after the procedure, each mini-pig in group 2 was
anesthetized again without intubation. ECSW therapy was applied
to group 2 animals on day 90 after the procedure using the shock
wave generator system (Cardiospec, Medispec, Israel). A cardiac
ultrasound imaging system was used to locate the treatment areas
of left ventricle. Under transthoracic sonographic guidance, shock
waves were then delivered via a special applicator through the
anatomical acoustic window to the treatment area under ECG R-
wave gating. Briefly, after echocardiographic localization of the
four ischemic zones of LV (i.e. middle anterior, middle
anteroseptal, middle inferior, and middle inferolateral segments)
using parasternal axis approach, ECSW was applied once to each
of the four ischemic zones at an intensity of 200 impulses at
0.09 mJ/mm
2/zone which was a dosage modified according to a
previous report [15] so that the total energy applied to LV
myocardium was 800 impulses at 0.09 mJ/mm
2.
Functional Assessment by Echocardiography
Transthoracic echocardiography was performed preoperatively
and on days 90 and 180 after the procedure under general
anesthesia as described previously [22] using an ultrasound system
(Hewlett Packard SONOS 7500) equipped with 2.5 to 3.5 MHz
linear probes. With the animals in a supine position, left
ventricular internal dimensions [i.e. end-systolic diameter (ESD)
and end-diastolic diameter (EDD)] were measured according to
the American Society of Echocardiography leading-edge method
using at least 3 consecutive cardiac cycles [22].
The LV ejection fraction (LVEF) was calculated as: LVEF (%)
= [(LVEDD
32LVEDS
3)/LVEDD
3] x 100. All measurements
were performed by a cardiologist blinded to treatment and non-
treatment groups.
Cardiac Catheterization
By six months following the procedure, cardiac catheterization
was performed via right common carotid artery. A 6-French
pigtail was used for measuring the arterial blood pressure in
ascending aorta, LV systolic and end-diastolic pressure as well as
for performing left ventriculography. Coronary angiographic study
was achieved using a 6-French Kimny guiding catheter (Boston
Scientific, Scimed, Inc. Maple Grove, MN).
Left ventriculography, which was immediately performed after
the insertion of arterial sheath into right common carotid artery,
was recorded at 30u right anterior oblique and 60u left anterior
oblique views. The blood pressures of ascending aorta and LV
chambers as well as LVEF were then determined.
The mini-pigs were sacrificed by intra-coronary injection of
potassium chloride in catheterization room after the procedure.
The heart was carefully removed for further studies.
Immunohistochemical staining for CD40 and
Immunohistofluorescence staining for von Willebrand
Factor (vWF)
Paraffin sections (3 mm thick) were obtained from LV
myocardium of each mini-pig. To block the action of endogenous
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peroxide, and then further processed using Beat Blocker Kit
(Zymed Company, #50–300) with immersion in solutions A and B
for 30 minutes and 10 minutes, respectively, at room temperature.
Polyclonal rabbit antibodies against CD40 (dilution 1/100; Spring
Bioscience) were then used, followed by application of Super-
PicTure
TM Polymer Detection Kit (Zymed) for 10 minutes at
room temperature. Finally, the sections were counterstained with
hematoxylin. For negative control experiments, primary antibod-
ies were omitted.
Immunohistofluorescence (IHF) staining for vWF-positive cells,
an index of endothelial cells in capillaries, was performed with
anti-vWF antibody (Chemicon).
Oxidative Stress Reaction of LV Myocardium
The Oxyblot Oxidized Protein Detection Kit was purchased
from Chemicon (S7150). The procedure was performed according
to our recent study [23]. The 2,4-Dinitrophenylhydrazine (DNPH)
derivatization was carried out on 6 mg of protein for 15 minutes
according to manufacturer’s instructions. One-dimensional elec-
trophoresis was carried out on 12% SDS/polyacrylamide gel after
DNPH derivatization. Proteins were transferred to nitrocellulose
membranes which were then incubated in the primary antibody
solution (anti-DNP 1:150) for 2 hours, followed by incubation with
second antibody solution (1:300) for one hour at room temper-
ature. The washing procedure was repeated eight times within 40
minutes. Immunoreactive bands were visualized by enhanced
chemiluminescence (ECL) which was then exposed to Biomax L
film (Kodak). For quantification, ECL signals were digitized using
Labwork software (UVP). On each gel, a standard control sample
was loaded.
Isolation of Mitochondria for Cytochrome C and
Connexin (Cx)43
The LV myocardium was excised and then washed with buffer
A (100 mM Tris-HCl, 70 mM sucrose, 10 mM EDTA and
210 mM mannitol, pH 7.4). Samples were minced finely in cold
buffer A and then incubated for 10 min. All samples were
homogenized in an additional 3 mL of buffer A using a motor-
driven grinder. The homogenate was centrifuged twice at 700 g
Figure 1. Detailed protocol and procedure. Schematic illustration of the detailed protocol on preparative procedure of extracorporeal shock
wave (ECSW) therapy. LAD=left anterior descending artery.
doi:10.1371/journal.pone.0024342.g001
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8,500 g for 15 min, and the pellets were washed with buffer B
(10 mM Tris-HCl, 70 mM sucrose, 1 mM EDTA, and 230 mM
mannitol, pH 7.4). The mitochondria-rich pellets were collected
and stored at 270uC.
Western Blot Analysis for Connexin 43, CXCR4, Stromal
Cell-Derived Factor (SDF)-1a, and Cytochrome C in LV
Myocardium
Equal amounts (10–30 mg) of protein extracts from remote
viable LV myocardium were loaded and separated by SDS-PAGE
using 8–10% acrylamide gradients. Following electrophoresis, the
separated proteins were transferred electrophoretically to a
polyvinylidene difluoride (PVDF) membrane (Amersham Biosci-
ences). Nonspecific proteins were blocked by incubating the
membrane in blocking buffer (5% nonfat dry milk in T-TBS
containing 0.05% Tween 20) overnight. The membranes were
incubated with the indicated primary antibodies (Cx43, 1:1000,
Chemicon; CXCR4, 1:1000, Abcam; SDF-1, 1:1000, Cell
Signaling; cytochrome C, 1: 1000, BD Biosciences; Actin,
1:10000, Chemicon) for 1 h at room temperature for Cx43,
cytochrome C and CXCR4 and overnight at 4uC for SDF-1a,
respectively. Horseradish peroxidase-conjugated anti-mouse im-
munoglobulin IgG (1:2000, Amersham Biosciences) was applied as
the second antibody for Cx43 for 1 h at room temperature;
Horseradish peroxidase-conjugated anti-rabbit immunoglobulin
IgG (1:2000, Cell Signaling) was applied as the secondary antibody
for one hour for Cx43, cytochrome C and CXCR4 and 45
minutes for SDF-1a at room temperature. The washing procedure
was repeated eight times within 1 h.
Real-Time quantitative PCR Analysis
Real-time polymerase chain reaction (PCR) was conducted
using LighCycler TaqMan Master (Roche, Germany) in a single
capillary tube according to the manufacturer’s guidelines for
individual component concentrations. Forward and reverse
primers were each designed based on individual exon of the
target gene sequence to avoid amplifying genomic DNA.
During PCR, the probe was hybridized to its complementary
single-strand DNA sequence within the PCR target. As amplifi-
cation occurred, the probe was degraded due to the exonuclease
activity of Taq DNA polymerase, thereby separating the quencher
from reporter dye during extension. During the entire amplifica-
tion cycle, light emission increased exponentially. A positive result
was determined by identifying the threshold cycle value at which
reporter dye emission appeared above background.
Vessel Density in LV Myocardium
Immunohistochemical (IHC) staining of arterioles was per-
formed with a-SMA (1:400) as primary antibody at room
temperature for 1 h, followed by washing with phosphate buffered
saline (PBS) thrice. The anti-mouse-horseradish peroxidase-
conjugated (HRP) conjugated secondary antibody was then added
for 10 min, followed by washing with PBS thrice. The 3, 3’
diaminobenzidine (DAB) (0.7 gm/tablet) (Sigma) was added for 1
minute, followed by washing with PBS thrice. Finally, hematoxylin
was added for 1 minute as a counter stain for nuclei, followed by
washing twice. Three coronal sections of the heart were analyzed
in each mini-pig. For quantification, three randomly selected high-
power fields (HPFs) (x200) were analyzed in each slide. The mean
number per HPF for each animal was then determined by
summation of all numbers divided by 9.
Histological Study of Fibrosis Area
Masson’s trichrome staining was used for studying fibrosis of LV
myocardium. Three serial sections of LV myocardium were
prepared at 4 mm thickness by Cryostat (Leica CM3050S). The
integrated area (mm
2) of fibrosis in the slides was calculated using
Image Tool 3 (IT3) image analysis software (University of Texas,
Health Science Center, San Antonio, UTHSCSA; Image Tool for
Windows, Version 3.0, USA). Three selected sections were
quantified for each animal. Three randomly selected HPFs (400
x) were analyzed in each section. After determining the number of
pixels in each fibrotic area per HPF, the numbers of pixels
obtained from the three HPFs were summed. The procedure was
repeated in two other slides for each animal. The mean pixel
number per HPF for each animal was then determined by
summating all pixel numbers and dividing by 9. The mean the
integrated area (mm
2) of fibrosis in LV myocardium per HPF was
obtained using a conversion factor of 19.24 (1 mm
2 represented
19.24 pixels).
TUNEL Assay for Apoptotic Nuclei
For each animal, 6 sections (3 longitudinal and 3 transverse
sections of LV myocardium) were analyzed by an in situ Cell Death
Detection Kit, AP (Roche) according to the manufacture’s
guidelines. The TUNEL-positive cells was examined in 3
randomly chosen HPF (6400) and normalized to the total number
of cells divided by 18.
Statistical Analysis
Data were expressed as mean values (mean 6 SD). The
significance of differences between two groups was evaluated with
t-test. The significance of differences among the groups was
evaluated using analysis of variance followed by Bonferroni
multiple-comparison post hoc test. Statistical analyses were
performed using SAS statistical software for Windows version
8.2 (SAS institute, Cary, NC). A probability value ,0.05 was
considered statistically significant.
Results
Serial Echocardiography Findings and Six-Month
Angiographic Findings
There were no significant differences in initial and day 90
LVEDD, LVESD, left ventricular end-diastolic volume (LVEDV),
left ventricular end-systolic volume (LVESV), LVEF and FS
between group 1 (without ECSW therapy) and group 2 (with
ECSW therapy) (Table 1). Moreover, LVEDD and LVEDV were
similar between group 1 and group 2 on day 180 after the
procedure. However, LVESD (2.9760.58 vs. 2.2460.31,
p=0.021) and LVESV (36.0617.4 vs. 17.266.3, p=0.032) were
significantly higher, whereas LVEF (43.7610.1 vs. 63.969.9,
p=0.006) and FS (20.965.5 vs. 36.167.3, p=0.002) were
significantly lower in group 1 than in group 2 on day 180 after
the procedure. Furthermore, using paired two-tailed t-test for
LVEDD between 90 day and 180 day in the same group, this
parameter was found to be significantly reduced in group 2
(4.0260.46 vs. 3.5260.48, p=0.043), but it showed no difference
in group 1 (3.7060.45 vs. 3.7360.49, p=0.897). These findings
imply that ECSW therapy attenuated ischemia-related LV
remodeling and improved ischemia-related LV dysfunction. Of
importance is the fact that no ECSW therapy-related side effect
was observed.
Six-month angiographic results showed that the systolic or
diastolic blood pressure of ascending aorta and LV systolic
pressure were similar between group 1 and group 2. However, LV
Shock Wave Reverses Ischemic Heart Dysfunction
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8.462.7, p,0.001), whereas LVEF (43.869.6 vs. 62.568.4,
p=0.004) was substantially lower in group 1 than in group 2 (all
p,0.005). These findings further support the effect of ECSW
therapy on inhibiting LV remodeling and improving LV function
in the setting of myocardial ischemia.
Protein Expressions of Mitochondrial Oxidative Stress
and Cytochrome C in Mitochondria and Cytosol of LV
Myocardium
Compared with normal controls, Western blotting revealed
notably enhanced mitochondrial oxidative stress (Fig. 2A) in
groups 1 and 2 (all p,0.001). Moreover, the protein expression of
oxidative stress in mitochondria was remarkably increased in
group 1 than in group 2 (p,0.05). The total cytochrome C protein
expression in both mitochondria (Fig. 2B) and cytosol (Fig. 2C) did
not differ between normal controls and group 2, whereas its
expression in mitochondria was significantly reduced in group 1 as
compared with normal controls and group 2 (all p,0.04). In
contrast, its cytosolic expression was significantly enhanced in
group 1 compared to normal controls and group 2 (all p,0.04).
These findings indicate that the expression of cytochrome C, an
index of energy supply and storage in mitochondria, was relatively
well-preserved in group 2 compared with that in group 1. The
increase in cytosolic cytochrome C content also suggests significant
mitochondrial damage with cytochrome C release into the cytosol
in the myocardium of group 1 animals. These findings highlight
the fact that ECSW therapy significantly alleviated the intensity of
oxidative stress resulting from free radical production due to a
change in permeability of the mitochondrial transition pore after
myocardial ischemia.
Angiogenesis-related protein expression of CXCR4, SDF-1
and VEGF and Cx43 of LV Myocardium
The protein expressions of CXCR4 (Fig. 2D), an index of
endothelial progenitor cells (EPCs), and SDF-1a (Fig. 2E), a
chemokine for EPCs homing in ischemic tissue, were remarkably
higher in group 2 as compared with those in normal controls and
in group 1, and notably higher in group 1 than in normal controls
(all p,0.05). Moreover, VEGF (Fig. 2F), an index of chemokine
for angiogenesis, was notably higher in group 2 than in both
normal controls and group 1, and significantly higher in group 1
than in normal controls (all p,0.03). These findings indicate that
EPCs, SDF-1a and VEGF were increased in response to ischemic
stimuli and ECSW therapy enhanced these cellular and
chemokine expressions for angiogenesis which, in turn, leaded
to an increase in the number of endothelial cells in ischemic
tissue.
The protein expression of Cx43 (Fig. 2G), an indicator of the
integrity of signal transduction and communication between
cardiomyocytes, was significantly lower in group 1 than in both
normal controls and group 2, and was notably lower in group 2
than in normal controls (all p,0.005).
Apoptosis and Fibrosis of LV Myocardium
TUNEL assay (Fig. 3, A–D) identified notably higher
n u m b e ro fa p o p t o t i cn u c l e ii ng r o u p1t h a nt h a ti nb o t h
normal controls and group 2, and remarkably higher in group 2
than in normal controls (all p,0.001). Furthermore, Masson’s
trichrome staining (Fig. 3, E–H) showed markedly increased
fibrotic area in group 1 compared with that in normal controls
and group 2, and significantly higher in group 2 than in normal
controls (all p,0.0001). These findings may suggest that ECSW
therapy attenuated cardiomyocyte death and myocardial
fibrosis.
Intensification of IHF and IHC Staining
The results of IHF staining demonstrated that the numbers of
CXCR4-, SDF-1a-, vWF-, and CD31-positive cells (Fig. 4 and 5)
were remarkably higher in group 2 than in both normal controls
and group 1 in LV myocardium (all p,0.001). Besides, the
numbers of vWF- and CD31-positive cells (Fig. 4) were
significantly higher in normal controls than in group 1 (all
p,0.01). In contrast, the numbers of both CXCR4- and SDF-1a-
positive cells (Fig. 5) were notably higher in group 1 than in
normal controls (all p,0.01). IHC staining revealed that the
number of small vessel (#25 mm in diameter) (Fig. 6, A–D) was
Table 1. Serial Echocardiography Findings and Six-Month
Angiographic results of the Animals.
Variables
Group 1*
(n=6)
Group 2*
(n=6) p-value
Echocardiography (Day-0)
LVEDD (cm) 3.2360.43 3.5661.46 0.090
LVESD (cm) 2.3160.36 2.5960.13 0.082
LVEDV (mL) 43.0613.1 53.565.1 0.093
LVESV (mL) 18.966.9 24.163.4 0.110
FS (%) 28.761.9 27.860.9 0.268
LVEF (%) 56.663.3 54.761.5 0.224
Echocardiography (Day-90)
LVEDD (cm) 3.7060.45 4.0260.46 0.866
LVESD (cm) 2.7660.54 2.7160.46 0.861
LVEDV (mL) 59.4615.6 57.5616.1 0.851
LVESV (mL) 30.1613.7 28.2611.0 0.806
FS (%) 25.867.1 26.364.1 0.798
LVEF (%) 51.5612.7 52.166.9 0.764
Echocardiography (Day-180)
LVEDD (cm) 3.7360.49 3.5260.48 0.474
LVESD (cm) 2.9760.58 2.2460.31 0.021
LVEDV (mL) 57.4621.3 52.2616.5 0.650
LVESV (mL) 36.0617.4 17.266.3 0.032
FS (%) 20.965.5 36.167.3 0.002
LVEF (%) 43.7610.1 63.969.9 0.006
Angiographic Results (Day-180)
LVEF (%) 43.869.6 62.568.4 0.004
SBP of AsAo (mmHg) 154.269.9 141.1627.0 0.327
DBP of AsAo (mmHg) 123.666.20 101.9622.3 0.06
LVSBP (mmHg) 140.465.3 133.5620.6 0.394
LVEDP (mmHg) 18.664.8 8.462.7 ,0.001
180-day mortality 0% (0) 0% (0) —
Malignant dysrhythmia 0% (0) 0% (0) —
Data are expressed as mean 6SD or %.
LVEDD=left ventricular end-diastolic dimension; LVESD=left ventricular end-
systolic dimension; LVEDV=left ventricular end-diastolic volume; LVESV=left
ventricular end-systolic volume; FS=fraction shortening; LVEF=left ventricular
ejection fraction; SBP of AsAo=systolic blood pressure of ascending aorta;
DBP=diastolic blood pressure; LVEDP=left ventricular end-diastolic pressure.
*group 1=ischemia without extracorporeal shock wave (ECSW) treatment;
group 2=ischemia plus ECSW-treated.
doi:10.1371/journal.pone.0024342.t001
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24342Figure 2. Expression of oxidative stress- and angiogenesis-related proteins in LV myocardium. A) Protein expression of oxidative stress.
{p,0.001 between the indicated groups. B) Protein expression of cytochrome C in mitochondrial level. {p,0.04 between the indicated groups. C)
Protein expression of cytochrome C in cytosolic level. {p,0.04 between the indicated groups. D) Protein expression of CXCR4. {p,0.03 between the
indicated groups. E) Protein expression of stromal cell-derived factor (SDF)-1a. {p,0.05 between the indicated groups. F) Protein expression of VEGF.
{p,0.03 between the indicated groups. G) Protein expression of connexin43 (Cx43). {p,0.005 between the indicated groups. Symbols (*, {, {)
indicate significance (at 0.05 level) (by one-way ANOVA and Bonferroni multiple comparison post hoc test, n=6 in each group).
doi:10.1371/journal.pone.0024342.g002
Figure 3. Immunohistochemical staining of fibrosis and apoptotic nuclei in LV myocardium. Upper Panel: TUNEL assay (400x) showing
notably higher number of apoptotic nuclei (red arrows) after ischemic insult (B) compared with normal controls (A) and ischemia following shock
wave treatment (C). {p,0.001 between the indicated groups (D). Scale bars in right lower corner represent 20 mm. n=6 in each group.
Lower Panel: Masson’s Trichrome staining (1006) showing remarkably higher fibrotic area (blue) following ischemia (F) than in normal controls (E)
and ischemia with shock wave treatment (G). {p,0.0001 between the indicated groups (H). Scale bars in right lower corner represent 100 mm. n=6
in each group.
doi:10.1371/journal.pone.0024342.g003
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1, and was significantly higher in normal controls than in group 1
(all p,0.002). On the other hand, IHC staining demonstrated that
the number of CD40-positive cells (Fig. 6, E–H), an index of
inflammation, was notably higher in group 1 than that in normal
controls and group 2, and was significantly higher in group 2 than
normal controls (all p,0.001). These findings indicate that ECSW
therapy, in addition to enhancing angiogenesis, was effective in
attenuating inflammatory response.
mRNA Expression Patterns of Chemokines, Inflammatory
Mediators, and Apoptotic Indexes in LV Myocardium
The mRNA expressions of vWF, SDF-1a, and CXCR4 (Fig.7,
A–C) were notably higher in group 2 than in controls and group 1,
and significantly higher in group 1 than in normal controls (all
p,0.01). In addition, mRNA expression of IL-8/Gro (Fig. 7D), an
EPC-homing chemokine, was notably elevated in group 2 than in
normal controls and group 1, and notably higher in group 1 than
in normal controls (all p,0.01).
Figure 4. Immunofluorescent staining of vWF and CD31 in LV myocardium. Upper Panel: Immunofluorescence staining (400x) showing
significantly lower number of vWF-positive cells (yellow arrows) after ischemia (B) than in normal controls (A) and ischemia with shock wave
treatment (C). {p,0.001 between the indicated groups (D). Scale bars in right lower corner represent 20 mm. Lower Panel: Immunofluorescence
staining (400x) showing notably lower number of CD31-positive cells (yellow arrows) after ischemia (F) than in normal controls (E) and ischemia with
shock wave treatment (G). {p,0.01 between the indicated groups (H). Scale bars in right lower corner represent 20 mm.
doi:10.1371/journal.pone.0024342.g004
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tion. The mRNA expression of eNOS (Fig. 7E), an index of NO
production, was remarkably suppressed in group 1 compared with
that in normal controls and group 2, and was notably lower in
group 2 than that in normal controls (all p,0.03). Moreover, the
mRNA expression of MMP-9 (Fig. 7F), a pro-inflammatory index,
was significantly elevated in group 1 than that in normal controls
and group 2, and notably higher in group 2 than in normal
controls (all p,0.04). On the other hand, the mRNA expression of
IL-10 (Fig. 7G), an anti-inflammatory index, was notably lower in
group 1 than in normal controls and group 2, and significantly
lower in group 2 than normal controls (all p,0.03). These findings
suggest that ECSW therapy exerted an anti-inflammatory effect.
The mRNA expressions of Bax (Fig. 7H) and caspase 3 (Fig. 7I),
two indicators of apoptosis, were substantially higher in group 1
than in normal controls and group 2, and significantly higher in
group 2 than in normal controls (all p,0.02). Conversely, the
mRNA expression of Bcl-2 (Fig. 7J), an index of anti-apoptosis, was
Figure 5. Immunofluorescent staining of CXCR4 and SDF-1a in LV myocardium. Upper Panel: Immunofluorescence staining (400x)
showing significantly lower number of CXCR4-positive cells (yellow arrows) in normal controls (A) than in ischemic animals without (B) and with (C)
shock wave treatment. *p,0.01 between the indicated groups (D). Scale bars in right lower corner represent 20 mm. Lower Panel:
Immunofluorescence staining (400x) showing significantly lower number of SDF-1a-positive cells (yellow arrows) in normal controls (E) compared
with animals after ischemia without (F) and with (G) shock wave treatment. *p,0.01 between the indicated groups (H). Scale bars in right lower
corner represent 20 mm.
doi:10.1371/journal.pone.0024342.g005
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significantly lower in group 2 than in normal controls (all p,0.02).
These findings imply that ECSW therapy was anti-apoptotic.
The mRNA expression of PGC-1a (Fig. 7K), a transcriptional
coactivator for upstream regulator of lipid catabolism, oxidative
metabolism, mitochondrial metabolism and biogenesis, was notably
lower in group 1 than in both normal controls and group 2, and
significantly lower in group 2 than in normal controls (all p,0.02).
ThisfindingimplicatesECSW therapy reversed the downregulation
in PGC-1a gene expression in ischemia heart disease.
Discussion
This study, which investigated the impact of ECSW on
ischemia-related LV dysfunction, provided several striking impli-
cations. First, ECSW therapy markedly increased EPCs and EPC
homing-related chemokines in LV ischemic area, thereby
enhancing angiogenesis. Second, ECSW therapy remarkably
reduced inflammatory response, oxidative stress, cellular apopto-
sis, and fibrotic change in ischemic LV myocardium. Third, of
importance is the fact that ECSW substantially reversed ischemia-
Figure 6. Immunohistochemical staining of a-SMA and CD40 nuclei in LV myocardium. Upper panel: a-SMA immunohistochemical
staining (200x) showing notably lower number of small vessel (red arrows) after ischemia (B) than in normal controls (A) and ischemia with shock
wave treatment (C). {p,0.002 between the indicated groups (D). Scale bars in right lower corner represent 50 mm. Lower Panel: IHC staining (400x)
showing the CD40-positively stained cells were remarkably higher after ischemia (F) than in normal controls (E) and ischemia with shock wave
treatment (G). {p,0.001 between the indicated group (H). Scale bars in right lower corner represent 20 mm.
doi:10.1371/journal.pone.0024342.g006
Shock Wave Reverses Ischemic Heart Dysfunction
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24342Shock Wave Reverses Ischemic Heart Dysfunction
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24342related LV dysfunction and significantly attenuated ischemia-
induced LV remodeling without any side effect.
ECSW Therapy Improves Heart Function and Inhibits LV
Remodeling
Interestingly, while both clinical and experimental studies have
clearly shown that ECSW therapy improved recovery of chronic
hind limb ischemia and accelerated the healing process of ischemic
skin ulceration [24,25,26], the effect of ECSW therapy on
ischemia-related LV dysfunction has seldom been reported
[15,27]. The most important finding in the current study is that
ECSW treatment significantly reversed LV dysfunction and LV
remodeling. Besides, it is a non-invasive procedure with absolute
safety as demonstrated in the presented study. Practically, the
treatment for patients with severe diffuse CAD [12,13], so-called
‘‘end-stage coronary artery disease’’, remains a vexing problem for
interventional cardiologists and surgeons over several decades
because the majority of these patients are not suitable candidates
for either PCI or CABG. The results of our study, in addition to
supporting those from recent clinical observational studies [28,29],
also highlight the therapeutic potential of ECSW for patients with
severe diffuse-obstructive CAD unsuitable for PCI and CABG.
Mechanism of ECSW Therapy for Improving Heart
Function—Enhancement of Angiogenesis
One previous animal study has revealed that application of
ECSW in ischemic heart disease induced by restricting blood flow
over left circumflex artery improved ischemia-related LV
dysfunction through enhancing angiogenesis [15]. Besides, another
recent study using a myocardial ischemia-reperfusion injury model
in pigs has demonstrated that ECSW therapy enhanced protein
expressions of eNOS and VEGF in ischemic myocardium [27].
However, evidence of angiogenesis after ECSW therapy was only
supported by observation of an increased eNOS and VEGF in
myocardium and angiographic findings of increased capillary
density in that study [15,27]. Therefore, the precise mechanism
underlying ECSW-induced angiogenesis is still unclear [15]. One
important finding in the present study is that the mRNA
expressions of vWF, CXCR4, SDF-1a, eNOS, and IL-8/Gro
were remarkably higher in group 2 (Constrictor over LAD plus
ECSW) as compared with group 1 (Constrictor over LAD only). In
addition, the protein expressions of VEGF, SDF-1a and CXCR4
were also notably higher in group 2 than in group 1. Moreover,
IHF staining showed that the number of SDF-1a-, vWF-,
CXCR4-, and CD31-positive cells were substantially higher in
group 2 than in group 1. Furthermore, IHC staining for a-SMA
demonstrated that the number of small vessel in LV myocardium
was significantly higher in group 2 than in group 1. Our findings,
in addition to reinforcing and extending the findings of the
previous studies [15,27], also support that angiogenesis may
contribute to improved LV function after ECSW treatment.
Mechanism of ECSW Therapy for Improving Heart
Function—Attenuating Inflammatory Response,
Oxidative Stress, and Cellular Apoptosis
The association among inflammation, reactive oxygen species,
and cellular apoptosis/death has been fully investigated in the
setting of myocardial ischemia [30,31,32]. An important finding in
the present study is the notably lower mRNA expression of MMP-
9 and the remarkably elevated mRNA expression of IL-10 in LV
Figure 7. Profiles of mRNA expression in LV myocardium. 1) Notably higher mRNA expressions of vWF (A), SDF-1a (B), CXCR4 (C) and
interleukin (IL)-8/Gro (D) in ischemic animals with shock wave treatment compared with other groups. {p,0.01 between indicated groups. 2)
Remarkably lower mRNA expressions of eNOS (E) and IL-10 (G) after ischemia compared with other groups. {p,0.03 between indicated groups. 3)
Significantly higher mRNA expressions of matrix metalloproteinase (MMP)-9 (F), Bax (H), and caspase 3 (I) after ischemia than in other groups.
{p,0.04 between indicated groups. Notably higher mRNA expressions of Bcl-2 (J) and PGC-1a (K) in animals after ischemic insult with shock wave
treatment compared to those without. {p,0.02 between indicated groups.
doi:10.1371/journal.pone.0024342.g007
Figure 8. The proposed mechanisms. Proposed mechanisms of extra-corporeal shock wave therapy on improving left ventricular (LV) function
and attenuating LV remodeling in a porcine model of ischemic heart disease.
doi:10.1371/journal.pone.0024342.g008
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procedure. Furthermore, the significantly reduced oxidative stress
and the suppression of CD40-positive cells in LV myocardium
after ECSW administration imply significant roles of ECSW in
attenuating inflammation and oxidative stress in ischemic
myocardium.
Importantly, ECSW therapy also remarkably reduced the
mRNA expressions of Bax and caspase 3 and significantly
increased the mRNA expression of Bcl-2. The anti-apoptotic
action of ECSW was further confirmed by TUNEL staining of LV
myocardium. Furthermore, ECSW treatment also significantly
reduced fibrosis of LV myocardium. Of importance is that ECSW
therapy significantly preserved the level of PGC-1a gene
expression and mitochondrial cytochrome C and maintained the
protein expression of Cx43 in LV myocardium which have been
shown to be depressed in the setting of dilated cardiomyopathy
[33]. These findings further strengthen the therapeutic potential of
ECSW in reversing ischemia-related LV dysfunction and remod-
eling through inhibiting cellular apoptosis/death and myocardial
fibrosis as well as preserving the integrities of Cx43 and energy
biogenesis and metabolism which plays a key role in electrical
coupling between cardiomyocytes [34,35].
In conclusion, ECSW therapy significantly reversed ischemia-
related LV remodeling and preserved LV function through
enhancing angiogenesis, attenuating inflammation, and suppress-
ing oxidative stress. The proposed mechanisms of potential
impacts of ECSW therapy on preserving heart function in the
porcine model have been summarized in Figure 8.
Study Limitations
This study has limitations. First, since serial studies on the cause-
and-effect relationship using different dosages of ECSW have not
been performed, the optimal dosage for maximal therapeutic
effects within safety margin is still unknown. Additionally, the
sample size of the current study was relatively small. However, the
impact of our results, on the other hand, is impressive. Second, this
study did not investigate in details the mechanistic basis of ECSW
therapy underlying the observed pro-angiogenic, anti-inflamma-
tory, and anti-oxidant effects at molecular-cellular level. Further
studies, therefore, may be warranted to clarify a cause-and-effect
relationship when it comes to mechanistic findings of ESCW
treatment against ischemic cardiac dysfunction and remodeling.
Third, this study did not examine the effect of ECSW therapy on
normal mini-pig myocardium. Thus, we did not provide
information on the possibility of enhancement of angiogenesis
through ECSW on normal mini-pig myocardium.
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